362 related articles for article (PubMed ID: 29714133)
1. Drugs for Targeted Therapies of Alzheimer's Disease.
Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
[TBL] [Abstract][Full Text] [Related]
2. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
3. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
Kalra J; Khan A
Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
[TBL] [Abstract][Full Text] [Related]
4. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
8. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
Lin LF; Luo HM
Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
[TBL] [Abstract][Full Text] [Related]
9. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
10. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
West S; Bhugra P
Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
[TBL] [Abstract][Full Text] [Related]
11. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies.
Zheng Q; Kebede MT; Kemeh MM; Islam S; Lee B; Bleck SD; Wurfl LA; Lazo ND
Molecules; 2019 Jun; 24(12):. PubMed ID: 31234523
[TBL] [Abstract][Full Text] [Related]
13. Progress in the development of new drugs in Alzheimer's disease.
Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
[TBL] [Abstract][Full Text] [Related]
14. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
15. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
Suzuki N; Hatta T; Ito M; Kusakabe KI
Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
17. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
18. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
19. Status and future directions of clinical trials in Alzheimer's disease.
Plascencia-Villa G; Perry G
Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
[TBL] [Abstract][Full Text] [Related]
20. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]